[ad_1]
Dr. Valeriu Gheorghiță, coordinator of the national vaccination campaign in Romania, stated in Digi24 that those who were vaccinated with the AstraZeneca group who arrived in the country do not have to panic, as there is no evidence to show a link between the vaccine. and adverse events reported in other countries. It also specified that thrombotic events will be assessed.
“Thrombotic events involve the development of blood clots and can cause medical consequences depending on the location of that clot. From this point of view, we do not have a particular attitude towards people vaccinated both with the doses of lot 2856 and with those of the other types of vaccines.
From a statistical point of view, as in the general unvaccinated population, there are different probabilities of cardiovascular and neurological events. In Romania, the main cause of death is cardiovascular disease.
For all these reasons, and given the frequency of these reported events, centralized at the European level, it does not present a greater incidence than is usually the case among the population. No particular behavior is required at this time for these people who have already been vaccinated.
We must not panic. When there are changes in health, we contact the family doctor or the emergency service, but we should not panic at this time because this is not the case.“Gheorghiță stated, on Digi24.
“Italy has raised suspicions about the occurrence of two major thrombotic events in an ABV2856 group and has decided to suspend vaccination with this type of vaccine in the group.
We made a very quick evaluation of the type of vaccine we received and the batches sent, in Romania the first tranche received on February 7th was from this lot, of approximately 81,600 doses and 77,049 doses of this second batch of ABV2856 were used.
4257 doses were left unused. They are in quarantine. Will remain. Once we have an EMA conclusion, we will decide what will happen to this lot.
Vaccination activity continues ”, he added.
During the afternoon of Thursday a meeting was held attended by representatives of CNCAV, INSP, Ministry of Health, NAMMD, in which the situation of the two batches of vaccines was analyzed.
The decisions were as follows, according to a CNCAV statement:
“1. As a precautionary measure, it was decided to temporarily quarantine the remaining doses until the evaluation of the European Medicines Agency is completed;
2. Vaccination is continued with all other vaccines from the pharmaceutical company AstraZeneca from the other batches that currently exist in Romania;
3. Replace the 4257 unused doses in the vaccination centers so that the immunization process is not affected.
We mention the fact that this decision was taken as an extreme precautionary measure, without at this time in Romania there is any scientific argument that would have imposed this decision.
We reiterate that the decision to quarantine the respective batch was made exclusively on the basis of the event reported in Italy.
Today, 03.11.2021, as a result of the preliminary analysis of the cases of thromboembolic events reported in Austria regarding the ABV 5300 lot, the EMA issued an official statement announcing that at this time there is no indication of a causal link between the vaccines.
and reported adverse events ”, recalls the CNCAV.
It should be noted that in Romania no thromboembolic problems like those reported in other countries have occurred in people who have been vaccinated with AstraZeneca.
The European Medicines Agency (EMA) recommended on Thursday the “continuous administration” of AstraZeneca’s COVID-19 vaccine, emphasizing that there is currently no evidence of an increased risk of blood clotting (thrombosis) in people vaccinated with this serum.
Editing: Alexandru Costea
